MCID: BNS007
MIFTS: 47

Bone Sarcoma

Categories: Bone diseases, Cancer diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Bone Sarcoma

MalaCards integrated aliases for Bone Sarcoma:

Name: Bone Sarcoma 11 58 14 75

Characteristics:


Prevelance:

1-9/1000000 (Europe) 1-9/100000 (Europe) 58

Classifications:

Orphanet: 58  
Rare bone diseases


External Ids:

Disease Ontology 11 DOID:0080639
UMLS via Orphanet 72 C0029463 C1704327
Orphanet 58 ORPHA223727

Summaries for Bone Sarcoma

Disease Ontology: 11 A bone cancer that has material basis in abnormally proliferating cells derives from embryonic mesoderm.

MalaCards based summary: Bone Sarcoma is related to muscle cancer and clear cell chondrosarcoma. An important gene associated with Bone Sarcoma is MTAP (Methylthioadenosine Phosphorylase), and among its related pathways/superpathways are MicroRNAs in cardiomyocyte hypertrophy and miRNAs involved in DNA damage response. The drugs Heparin, bovine and Reviparin have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and lung.

Wikipedia: 75 A bone sarcoma is a primary malignant bone tumour, a type of sarcoma that starts in the bones. This is... more...

Related Diseases for Bone Sarcoma

Diseases related to Bone Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 381)
# Related Disease Score Top Affiliating Genes
1 muscle cancer 32.1 SERPINA3 MIR9-1 MIR199A1 H2AC18
2 clear cell chondrosarcoma 31.9 SERPINA3 H2AC18
3 ewing sarcoma 31.5 MIR9-1 MIR214 MIR199A1 MIR193A KDM4C H2AC18
4 bone cancer 30.6 SERPINA3 MIR9-1 MIR338 MIR335 MIR214 MIR199A1
5 toxic encephalopathy 30.6 SERPINA3 MIR9-1 MIR142 H2AC18
6 kidney cancer 30.2 MIR214 MIR199A1 MIR193A MIR17 MIR142 H2AC18
7 cervical cancer 30.1 MIR338 MIR214 MIR193A MIR17 MIR143 MIR140
8 bone inflammation disease 30.0 SERPINA3 MIR9-1 MIR338 MIR335 MIR214 MIR199A1
9 breast cancer 29.8 SERPINA3 MIR9-1 MIR335 MIR214 MIR199A1 MIR195
10 head and neck cancer 29.7 MIR9-1 MIR542 MIR338 MIR335 MIR199A1 MIR195
11 osteogenic sarcoma 11.4
12 diaphyseal medullary stenosis with malignant fibrous histiocytoma 11.3
13 chondrosarcoma 11.2
14 soft tissue sarcoma 11.1
15 bone giant cell tumor 11.0
16 sarcoma 11.0
17 fibrosarcoma of bone 11.0
18 mesenchymal chondrosarcoma 11.0
19 short stature, onychodysplasia, facial dysmorphism, and hypotrichosis 10.7
20 cervix small cell carcinoma 10.5 MIR199A1 MIR143 MIR100
21 diffuse astrocytoma 10.5 SERPINA3 KDM4C H2AC18
22 mixed cell type cancer 10.5 SERPINA3 MIR542 H2AC18
23 tonsil cancer 10.5 SERPINA3 MIR199A1 H2AC18
24 macular holes 10.5 SERPINA3 MIR9-1 MIR199A1
25 mixed hepatoblastoma 10.5 SERPINA3 MIR624
26 skeletal muscle cancer 10.5 SERPINA3 MIR9-1 MIR199A1 H2AC18
27 interstitial lung disease 10.5 SERPINA3 MIR214 MIR199A1 MIR142 H2AC18
28 esophagus adenocarcinoma 10.5 MIR199A1 MIR193A MIR143
29 ovarian clear cell carcinoma 10.5 MIR9-1 MIR199A1 H2AC18
30 alcohol use disorder 10.5 SERPINA3 MIR199A1 KDM4C H2AC18
31 substance abuse 10.5 SERPINA3 MIR9-1 MIR199A1 H2AC18
32 lymphangioma 10.5 SERPINA3 MIR199A1 MIR143 H2AC18
33 central nervous system lymphoma 10.5 MIR9-1 MIR199A1 KDM4C
34 childhood leukemia 10.5 MIR335 KDM4C H2AC18
35 colonic benign neoplasm 10.5 SERPINA3 MIR199A1 MIR143 H2AC18
36 placenta disease 10.5 SERPINA3 MIR199A1 MIR181A1 H2AC18
37 pleuropulmonary blastoma 10.5 MIR9-1 MIR214 MIR140
38 fetal alcohol spectrum disorder 10.5 MIR9-1 MIR140 KDM4C H2AC18
39 melanoma in congenital melanocytic nevus 10.5 MIR199A1 KDM4C H2AC18
40 fetal alcohol syndrome 10.5 MIR9-1 KDM4C H2AC18
41 endometrial adenocarcinoma 10.5 SERPINA3 MIR199A1 MIR193A
42 autoimmune disease of gastrointestinal tract 10.5 SERPINA3 MIR199A1 MIR142 H2AC18
43 lung disease 10.5 SERPINA3 MIR199A1 MIR17 MIR142 H2AC18
44 mature t-cell and nk-cell lymphoma 10.5 MIR199A1 MIR17 KDM4C H2AC18
45 oropharynx cancer 10.5 SERPINA3 MIR199A1 H2AC18
46 reproductive organ benign neoplasm 10.4 MIR199A1 MIR142 H2AC18
47 rhabdoid cancer 10.4 MIR9-1 KDM4C H2AC18
48 mental depression 10.4 SERPINA3 MIR9-1 MIR142 H2AC18
49 aortic aneurysm, familial abdominal, 1 10.4 SERPINA3 MIR199A1 MIR195 MIR181A1 H2AC18
50 cerebral arterial disease 10.4 SERPINA3 MIR181A1 MIR143

Graphical network of the top 20 diseases related to Bone Sarcoma:



Diseases related to Bone Sarcoma

Symptoms & Phenotypes for Bone Sarcoma

Drugs & Therapeutics for Bone Sarcoma

Drugs for Bone Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
2
Reviparin Approved, Investigational Phase 4 9041-08-1
3
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
4 Antirheumatic Agents Phase 4
5 Fibrinolytic Agents Phase 4
6 Calcium heparin Phase 4
7 Anticoagulants Phase 4
8 Heparin, Low-Molecular-Weight Phase 4
9 Analgesics Phase 4
10 Antipyretics Phase 4
11 Cyclooxygenase Inhibitors Phase 4
12 Platelet Aggregation Inhibitors Phase 4
13 Anti-Inflammatory Agents, Non-Steroidal Phase 4
14 Analgesics, Non-Narcotic Phase 4
15 Anti-Inflammatory Agents Phase 4
16
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
17
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
18
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
19
Cisplatin Approved Phase 1, Phase 2 15663-27-1 2767 5702198 441203
20
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
21
Dacarbazine Approved, Investigational Phase 1, Phase 2 4342-03-4 2942 5351166
22
Epirubicin Approved Phase 1, Phase 2 56420-45-2 41867
23
Sunitinib Approved, Investigational Phase 1, Phase 2 557795-19-4 5329102
24
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
25
Aldesleukin Approved Phase 2 110942-02-4
26
Nivolumab Approved Phase 2 946414-94-4
27
Ipilimumab Approved Phase 2 477202-00-9
28
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
29
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
30
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
31
Ascorbic acid Approved, Nutraceutical Phase 2 50-81-7 54676860 54670067 5785
32
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
33
Exatecan Investigational Phase 2 171335-80-1 18546929 151115
34
Palifosfamide Investigational Phase 1, Phase 2 31645-39-3 100427
35 topoisomerase I inhibitors Phase 2
36 Parenteral Nutrition Solutions Phase 2
37 Ferrosoferric Oxide Phase 2
38 Pharmaceutical Solutions Phase 2
39 Hypoglycemic Agents Phase 2
40 Alkylating Agents Phase 1, Phase 2
41 Antineoplastic Agents, Alkylating Phase 1, Phase 2
42 Angiogenesis Inhibitors Phase 1, Phase 2
43 Protein Kinase Inhibitors Phase 1, Phase 2
44 Anti-Retroviral Agents Phase 2
45 Interleukin-2 Phase 2
46 Anti-HIV Agents Phase 2
47 Immunoglobulins Phase 2
48 Immune Checkpoint Inhibitors Phase 2
49 Antibodies, Monoclonal Phase 2
50 Antibodies Phase 2

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
2 3D Gait Analysis to Determine Functional Limitations and Evaluate a Training Intervention in Young People With Tumor Endoprosthesis of the Lower Extremity Completed NCT04963517 Phase 2, Phase 3
3 PhaseⅡ Study of Weekly Docetaxel and Fixed-Dose Rate Gemcitabine in Patient With Previously Treated Advanced Soft Tissue and Bone Sarcoma Prospective, Open Label, Multi-Institutional Unknown status NCT00807261 Phase 2 Gemcitabine and Docetaxel
4 A Phase II Single Arm Study Assessing Efficacy & Safety of Nivolumab Plus Ipilimumab in Nonresectable/Metastatic Sarcoma and Endometrial Carcinoma Patients With Somatic Deficient MMR as a Selection Tool Unknown status NCT02982486 Phase 2 Ipilimumab;Nivolumab
5 Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma Completed NCT00802880 Phase 2 Dacarbazine
6 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
7 SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Completed NCT02301039 Phase 2 Pembrolizumab
8 Pilot Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI Completed NCT01336803 Phase 2 Feraheme
9 Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse Recruiting NCT04758000 Phase 2 Metformin Hydrochloride
10 Phase I-II Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Recruiting NCT03277924 Phase 1, Phase 2 Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent];Nivolumab 100 MG/10 ML [Opdivo];Epirubicin;Ifosfamide;Doxorubicin;Dacarbazine;Cisplatin;Methotrexate
11 A Randomized, Placebo-controlled, Double-blinded, Phase II Study of Efficacy of Regorafenib as Maintenance Treatment in Patients With High Grade Bone Sarcomas at Diagnosis or Relapse and Without Complete Remission After Standard Treatment Recruiting NCT04698785 Phase 2 Treatment by regorafenib and best supportive care;Treatment by placebo and best supportive care
12 A Phase 1/ 2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-AXL-ADC, Alone and in Combination With a PD-1 Inhibitor in Adult Patients With Advanced Solid Tumors (Phase 1) and Adult and Adolescent Patients With Advanced, Refractory Sarcoma (Phase 2) Recruiting NCT03425279 Phase 1, Phase 2
13 Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable or Ablatable Sarcoma or Colorectal Pulmonary Metastases Recruiting NCT03965234 Phase 1, Phase 2 Cisplatin
14 Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine
15 Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma Active, not recruiting NCT02500797 Phase 2
16 A Randomised, Cross-over Phase II Study to Investigate the Efficacy and Safety of Glucarpidase for Routine Use After High Dose Methotrexate in Patients With Bone Sarcoma Terminated NCT02022358 Phase 2 Glucarpidase;Methotrexate;Folinic Acid
17 A Phase II Trial of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas in Adults Terminated NCT03468075 Phase 2 Ascorbate;Gemcitabine
18 A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Withdrawn NCT04906876 Phase 2 Gemcitabine;Docetaxel;9-ING-41
19 A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Withdrawn NCT05116800 Phase 2 Gemcitabine;9-ING-41;Docetaxel
20 An Open-Label Phase IB Trial To Evaluate the Effects of Food and Formulation on Pharmacokinetics of the Oral Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Soft-Tissue or Bone Sarcoma Completed NCT01896505 Phase 1 KCP-330
21 Phase I Dose-Escalation Study, to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 (Calcitriol, USP) in Adult Cancer Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Advanced or Recurrent Disease Completed NCT01588522 Phase 1 compound 31543 Calcitriol
22 To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Bone and Soft Tissue Sarcoma Recruiting NCT03462316 Phase 1
23 In Vivo Lung Perfusion (IVLP) as an Adjuvant Treatment for Patients Undergoing Surgical Resection of Pulmonary Metastases of Bone and Soft Tissues Sarcomas Active, not recruiting NCT02811523 Phase 1 Doxorubicin
24 A Phase I Trial of Dendritic Cell Vaccination for Children and Adults With Sarcoma Active, not recruiting NCT01803152 Phase 1 Gemcitabine;Imiquimod
25 A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma Not yet recruiting NCT05621668 Phase 1 Cyclophosphamide;attIL2-T cells
26 A European Treatment Protocol for Bone-sarcoma in Patients Older Than 40 Years Completed NCT02986503 Doxorubicin+cisplatin+ifosfamide;Doxorubicin+cisplatin+ifosfamide+methotrexate
27 DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study Completed NCT00525057 Dalteparin
28 A Phase II Study of Intensity Modulated Radiotherapy (IMRT) for Patients With Primary Bone and Soft Tissue Sarcoma Completed NCT02520128
29 Evaluation of Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma Recruiting NCT04735289
30 A Prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Patients With Soft-tissue and Bone Sarcoma Recruiting NCT04758325
31 Efficacy of Tranexamic Acid in Preventing Post Operative Blood Loss and Associated Complications in Bone Sarcoma Patients Treated With Limb Salvage Surgery: A Randomized Controlled Trial Recruiting NCT05427513 Early Phase 1 Tranexamic acid injection
32 Observational Study, for Quality Assessment, of Sarcoma as a Model to Improve Diagnosis and Clinical Care of Rare Tumors Through a European and Latin American Multidisciplinary NETWORK Recruiting NCT04181970
33 A Pilot Study of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas in Adults Recruiting NCT04634227 Early Phase 1 Ascorbate
34 A Randomized, Placebo-controlled, Double-blinded, Multicentre Study Evaluating the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas Recruiting NCT04055220 Treatment by Regorafenib;Treatment by Placebo
35 Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone Recruiting NCT05033288
36 Assessment of Healing and Function After Surgical Reconstruction for Osseous Sarcomas Recruiting NCT03442465
37 St. Judes-Stanford Comprehensive Support Initiative Active, not recruiting NCT03154190
38 Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients Active, not recruiting NCT05051059
39 Real-Time Contrast Enhanced Ultrasound and Ultrasound-Based Elastography: Novel Quantitative Imaging Techniques for Early Therapy Response Assessment in Sarcomas Active, not recruiting NCT02384473 Early Phase 1 Definity Suspension for Injection
40 Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas Active, not recruiting NCT00592293
41 A Pilot Study of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas Including Adolescents Not yet recruiting NCT04877587 Early Phase 1 Ascorbate;Gemcitabine
42 Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas (COSS-Registry) Not yet recruiting NCT05515068

Search NIH Clinical Center for Bone Sarcoma

Genetic Tests for Bone Sarcoma

Anatomical Context for Bone Sarcoma

Organs/tissues related to Bone Sarcoma:

MalaCards : Bone, T Cells, Lung, Lymph Node, Bone Marrow, Breast, Salivary Gland

Publications for Bone Sarcoma

Articles related to Bone Sarcoma:

(show top 50) (show all 1038)
# Title Authors PMID Year
1
Induced resistance to ifosfamide in osteosarcoma cells suggests a more aggressive tumor profile. 62
36213144 2022
2
The role of conventional radiography to assess the outcome of oncologic skeletal reconstructions of lower limbs aided by vascularized fibular autograft. 62
36442456 2022
3
Corrigendum to "SELNET clinical practice guidelines for bone sarcoma" Critical reviews in oncology/hematology, vol. 174 (2022), 1-10. 62
36220678 2022
4
Datasets for the reporting of primary tumour in bone: recommendations from the International Collaboration on Cancer Reporting (ICCR). 62
36464647 2022
5
Clinical outcomes of brain metastasectomy from soft tissue and bone sarcomas: a systematic review. 62
35994183 2022
6
Letter to Editor Referring to the Editorial by Istl et al. 'Good Bone Structure: A Call for Stronger Design and Methodology in Disparity Studies in Orthopedic Oncology' Discussing the Published Article: 'Non-Private Health Insurance Predicts Advanced Stage at Presentation and Amputation in Lower-Extremity High-Grade Bone Sarcoma: A National Cancer Database Study'. 62
35876922 2022
7
Correction to: ASO Author Reflections: Insurance-Related Disparities in High Grade Bone Sarcoma of Lower Extremity. 62
35428963 2022
8
A novel method of light projection and modular jigs to improve accuracy in bone sarcoma resection. 62
35245391 2022
9
Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks. 62
36074145 2022
10
Secondary osteosarcoma: a challenge indeed. 62
36401730 2022
11
Risk of subsequent primary lymphoma in a cohort of 69,460 five-year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study. 62
36444554 2022
12
Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study. 62
36319851 2022
13
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). 62
35980618 2022
14
Clinical features and overall survival of osteosarcoma of the mandible. 62
36243646 2022
15
Femoral Discrepancy After Childhood Bone Sarcoma Surgery Can Be Treated With Magnetic Intramedullary Nails. 62
36314876 2022
16
New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC - Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas. 62
36116829 2022
17
Correction to: Non-Private Health Insurance Predicts Advanced Stage at Presentation and Amputation in Lower Extremity High Grade Bone Sarcoma: A National Cancer Database Study. 62
35428962 2022
18
Management of chemotherapy-induced febrile neutropenia and use of granulocyte colony-stimulating factor in patients with soft tissue or bone sarcoma. 62
36226408 2022
19
Intercalary tibial reconstruction with frozen tumor-bearing autograft in combination with ipsilateral fibula in limb-salvage surgery. 62
35915017 2022
20
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study. 62
36077869 2022
21
Intermediate-term results and risk factors analysis of tumor endoprosthesis in paediatric patients after the resection of lower extremity bone sarcoma. 62
36207771 2022
22
Novel MAP4::RAF1 Fusion in a Primary Bone Sarcoma: Expanding the spectrum of RAF1 Fusion Sarcoma. 62
35156861 2022
23
Oncogenic Dysregulation of Circulating Noncoding RNAs: Novel Challenges and Opportunities in Sarcoma Diagnosis and Treatment. 62
36230599 2022
24
Individual Trajectories of Bone Mineral Density Reveal Persistent Bone Loss in Bone Sarcoma Patients: A Retrospective Study. 62
36143059 2022
25
SNHG9/miR-214-5p/SOX4 feedback loop regulates osteosarcoma progression. 62
36004648 2022
26
A calpain-6/YAP axis in sarcoma stem cells that drives the outgrowth of tumors and metastases. 62
36153320 2022
27
First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. 62
35561319 2022
28
The magnitude and perceived reasons for childhood cancer treatment abandonment in Ethiopia: from health care providers' perspective. 62
35941600 2022
29
Neoadjuvant Radiation in High-Grade Soft-Tissue Sarcomas: Histopathologic Features and Response Evaluation. 62
35687332 2022
30
Geographic Access to High-Volume Care Providers and Survival in Patients with Bone Sarcomas: Nationwide Patterns in the United States. 62
35730765 2022
31
Outcomes of Semiknee Replacement in Skeletally Immature Bone Sarcoma Patients. 62
35817056 2022
32
Work ability and physical activity after major bone sarcoma resection and reconstruction with tumour prosthesis of the lower extremities. A cross-sectional study. 62
35867957 2022
33
Does Primary Tumor Resection in Patients with Metastatic Primary Mobile Vertebral Column Sarcoma Improve Survival? 62
35439623 2022
34
What Proportion of Patients With Musculoskeletal Tumors Demonstrate Thromboelastographic Markers of Hypercoagulability? A Pilot Study. 62
35901446 2022
35
Dedifferentiated chondrosarcoma with minimal or small dedifferentiated component. 62
35115636 2022
36
What is the Cumulative Incidence of Revision Surgery and What Are the Complications Associated With Stemmed Cementless Nonextendable Endoprostheses in Patients 18 Years or Younger With Primary Bone Sarcomas About the Knee. 62
35171125 2022
37
Phyllodes Tumor as a Secondary Neoplasm in Survivors of Childhood Cancer: A Tertiary Care Cancer Centre Experience. 62
35129147 2022
38
Pediatric Osteosarcoma: Correlation of Imaging Findings with Histopathologic Features, Treatment, and Outcome. 62
35594197 2022
39
Outcomes of Osteosarcoma in Children Without High-Dose Methotrexate: Could It Be Less Toxic Without Effecting Survival Rates? 62
34342492 2022
40
The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis. 62
35312944 2022
41
Long-term outcomes of non-invasive expandable endoprostheses for primary malignant tumors around the knee in skeletally-immature patients. 62
33417027 2022
42
Blood-Derived Liquid Biopsies Using Foundation One® Liquid CDx for Children and Adolescents with High-Risk Malignancies: A Monocentric Experience. 62
35681754 2022
43
Proximal femoral replacement using the direct anterior approach to the hip. 62
35641789 2022
44
Risk survey for the population of Recife and neighboring cities due to the occurrence of radium in groundwater. 62
35305306 2022
45
Novel Positioning Feedback System as a Guidance in Bone Tumor Resection. 62
35658779 2022
46
SELNET clinical practice guidelines for bone sarcoma. 62
35460913 2022
47
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. 62
35705558 2022
48
Commentary: A Special Edition in bone sarcoma. 62
35517059 2022
49
3D-Printed Guides in Bone Tumor Resection: Studying Their Error and Determining a Safety Margin for Surgery. 62
35201939 2022
50
Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients. 62
34385340 2022

Variations for Bone Sarcoma

Cosmic variations for Bone Sarcoma:

8 (show all 49)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM95516578 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 6
2 COSM95520543 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 6
3 COSM95523461 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 6
4 COSM95526780 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 6
5 COSM87494413 GNAQ soft tissue,bone,sarcoma,NS c.442C>T p.R148* 9:77815650-77815650 6
6 COSM106056882 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 3
7 COSM111763021 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 3
8 COSM144313682 TP53 soft tissue,upper leg,sarcoma,NS c.524A>G p.H175R 17:7674890-7674890 3
9 COSM105659131 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 3
10 COSM93187807 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 3
11 COSM143375075 TP53 soft tissue,upper leg,sarcoma,NS c.524A>G p.H175R 17:7674890-7674890 3
12 COSM105624912 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 3
13 COSM122766413 TP53 soft tissue,upper leg,sarcoma,NS c.103C>T p.Q35* 17:7675113-7675113 3
14 COSM145021980 TP53 soft tissue,upper leg,sarcoma,NS c.524A>G p.H175R 17:7674890-7674890 3
15 COSM93215390 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 3
16 COSM143182864 TP53 soft tissue,upper leg,sarcoma,NS c.22C>T p.Q8* 17:7675113-7675113 3
17 COSM144334467 TP53 soft tissue,upper leg,sarcoma,NS c.382C>T p.Q128* 17:7675113-7675113 3
18 COSM143972614 TP53 soft tissue,upper leg,sarcoma,NS c.22C>T p.Q8* 17:7675113-7675113 3
19 COSM87902864 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 3
20 COSM112257156 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 3
21 COSM142564162 TP53 soft tissue,upper leg,sarcoma,NS c.524A>G p.H175R 17:7674890-7674890 3
22 COSM144655779 TP53 soft tissue,upper leg,sarcoma,NS c.524A>G p.H175R 17:7674890-7674890 3
23 COSM142840367 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 3
24 COSM122737959 TP53 soft tissue,upper leg,sarcoma,NS c.245A>G p.H82R 17:7674890-7674890 3
25 COSM144111084 TP53 soft tissue,upper leg,sarcoma,NS c.22C>T p.Q8* 17:7675113-7675113 3
26 COSM121881087 TP53 soft tissue,upper leg,sarcoma,NS c.245A>G p.H82R 17:7674890-7674890 3
27 COSM142860117 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 3
28 COSM144089819 TP53 soft tissue,upper leg,sarcoma,NS c.164A>G p.H55R 17:7674890-7674890 3
29 COSM144682712 TP53 soft tissue,upper leg,sarcoma,NS c.382C>T p.Q128* 17:7675113-7675113 3
30 COSM143159971 TP53 soft tissue,upper leg,sarcoma,NS c.164A>G p.H55R 17:7674890-7674890 3
31 COSM122275322 TP53 soft tissue,upper leg,sarcoma,NS c.245A>G p.H82R 17:7674890-7674890 3
32 COSM144041526 TP53 soft tissue,upper leg,sarcoma,NS c.466C>T p.Q156* 17:7675113-7675113 3
33 COSM142592590 TP53 soft tissue,upper leg,sarcoma,NS c.382C>T p.Q128* 17:7675113-7675113 3
34 COSM106084061 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 3
35 COSM112284809 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 3
36 COSM143401670 TP53 soft tissue,upper leg,sarcoma,NS c.382C>T p.Q128* 17:7675113-7675113 3
37 COSM122302302 TP53 soft tissue,upper leg,sarcoma,NS c.103C>T p.Q35* 17:7675113-7675113 3
38 COSM143947426 TP53 soft tissue,upper leg,sarcoma,NS c.164A>G p.H55R 17:7674890-7674890 3
39 COSM144017515 TP53 soft tissue,upper leg,sarcoma,NS c.608A>G p.H203R 17:7674890-7674890 3
40 COSM121910283 TP53 soft tissue,upper leg,sarcoma,NS c.103C>T p.Q35* 17:7675113-7675113 3
41 COSM111790424 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 3
42 COSM145045823 TP53 soft tissue,upper leg,sarcoma,NS c.382C>T p.Q128* 17:7675113-7675113 3
43 COSM87935416 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 3
44 COSM92479334 SH2B3 soft tissue,upper leg,sarcoma,NS c.232G>A p.E78K 12:111418377-111418377 3
45 COSM135372634 NUP93 soft tissue,upper leg,sarcoma,NS c.116C>T p.A39V 16:56748363-56748363 3
46 COSM88525472 NUP93 soft tissue,upper leg,sarcoma,NS c.116C>T p.A39V 16:56748363-56748363 3
47 COSM98577250 ANKRD11 soft tissue,upper leg,sarcoma,NS c.2882G>T p.R961L 16:89283660-89283660 3
48 COSM87618826 ANKRD11 soft tissue,upper leg,sarcoma,NS c.2882G>T p.R961L 16:89283660-89283660 3
49 COSM147901996 ANKRD11 soft tissue,upper leg,sarcoma,NS c.2882G>T p.R961L 16:89283660-89283660 3

Expression for Bone Sarcoma

Search GEO for disease gene expression data for Bone Sarcoma.

Pathways for Bone Sarcoma

Pathways related to Bone Sarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.72 MIR214 MIR199A1 MIR195 MIR140 MIR133A1
2 11.26 MIR542 MIR195 MIR181A1 MIR17 MIR143 MIR100
3
Show member pathways
11.06 MIR9-1 MIR214 MIR199A1 MIR181A1 MIR17 MIR143

GO Terms for Bone Sarcoma

Cellular components related to Bone Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.8 MIR100 MIR133A1 MIR140 MIR142 MIR143 MIR17
2 extracellular space GO:0005615 9.73 SERPINA3 MIR338 MIR335 MIR199A1 MIR181A1 MIR17
3 extracellular vesicle GO:1903561 9.46 MIR214 MIR193A MIR17 MIR100

Biological processes related to Bone Sarcoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.95 MIR9-1 MIR338 MIR214 MIR199A1 MIR17 MIR140
2 negative regulation of cell migration GO:0030336 9.91 MIR9-1 MIR338 MIR335 MIR214 MIR133A1
3 miRNA-mediated gene silencing GO:0035195 9.83 MIR100 MIR133A1 MIR140 MIR142 MIR143 MIR17
4 negative regulation of BMP signaling pathway GO:0030514 9.8 MIR100 MIR140 MIR17 MIR214
5 negative regulation of interleukin-6 production GO:0032715 9.75 MIR338 MIR195 MIR140
6 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.73 MIR9-1 MIR17 MIR100
7 negative regulation of vascular associated smooth muscle cell proliferation GO:1904706 9.71 MIR214 MIR140 MIR133A1
8 negative regulation of transporter activity GO:0032410 9.65 MIR9-1 MIR17 MIR133A1
9 negative regulation of osteoblast differentiation GO:0045668 9.65 MIR9-1 MIR214 MIR17 MIR140 MIR100
10 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.63 MIR199A1 MIR17 MIR133A1
11 positive regulation of connective tissue replacement GO:1905205 9.61 MIR214 MIR199A1 MIR195
12 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.58 MIR17 MIR133A1
13 cell growth involved in cardiac muscle cell development GO:0061049 9.57 MIR199A1 MIR195
14 negative regulation of xenobiotic detoxification by transmembrane export across the plasma membrane GO:1905700 9.55 MIR9-1 MIR133A1
15 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.54 MIR214 MIR199A1 MIR17
16 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.52 MIR17 MIR143
17 negative regulation of BMP secretion GO:2001285 9.5 MIR140 MIR17 MIR214
18 miRNA-mediated gene silencing by mRNA destabilization GO:0035279 9.46 MIR9-1 MIR214 MIR140 MIR100
19 negative regulation of vascular endothelial growth factor production GO:1904046 9.26 MIR199A1 MIR195 MIR17 MIR140

Molecular functions related to Bone Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA base-pairing translational repressor activity GO:1903231 9.77 MIR9-1 MIR338 MIR335 MIR214 MIR199A1 MIR195
2 mRNA 3'-UTR binding GO:0003730 9.44 MIR9-1 MIR338 MIR335 MIR214 MIR199A1 MIR195

Sources for Bone Sarcoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....